Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 28, 2015
SALT LAKE CITY, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the first subject dosed in its multi-dose PK dose finding...
-
Sep 22, 2015
SALT LAKE CITY, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Aug 31, 2015
SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug Application ("NDA") to the
-
Aug 10, 2015
SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as...
-
Aug 5, 2015
SALT LAKE CITY, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
-
Jun 29, 2015LPCN 1021 was well tolerated during 52 weeks of dosing
SALT LAKE CITY, June 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced top-line 52-week safety results from its Study of Oral Androgen...
-
Jun 15, 2015
SALT LAKE CITY, June 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
-
Jun 8, 2015
SALT LAKE CITY, June 8, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral...
-
Jun 2, 2015
SALT LAKE CITY, June 2, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted orphan...
-
May 11, 2015
SALT LAKE CITY, May 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
-
May 7, 2015
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as...
-
Apr 30, 2015
SALT LAKE CITY, April 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety...
-
Apr 29, 2015
SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
-
Apr 28, 2015
SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the closing of an underwritten public offering of 5,347,500...
-
Apr 24, 2015
SALT LAKE CITY, April 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
-
Apr 23, 2015
SALT LAKE CITY, April 23, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its...
-
Apr 10, 2015
SALT LAKE CITY, April 10, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
-
Mar 24, 2015
SALT LAKE CITY, March 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug Application ("NDA")...
-
Mar 11, 2015
SALT LAKE CITY, March 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as...
-
Mar 4, 2015
SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
-
Feb 27, 2015
SALT LAKE CITY, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement ("SOAR"
-
Feb 24, 2015
SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and Chief Executive Officer, and...
-
Jan 30, 2015
SALT LAKE CITY, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the...
-
Jan 12, 2015First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women
SALT LAKE CITY, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced successful top-line results of a Phase 1b study of LPCN 1107, the...
-
Dec 15, 2014
SALT LAKE CITY, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug...